Stock itci.
Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ITCI stock stock is $78.5, which predicts an increase of 34.05%. The lowest target is $62 and the highest is $101. On average, analysts rate ITCI stock stock as a strong buy.
seekingalpha.com - August 12 at 10:29 AM. GW&K Investment Management LLC Purchases 302,685 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 11 at 7:34 PM. Barclays PLC Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 8 at 6:11 AM.Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.ITCI Intra-Cellular. 10/02/23 RBC Capital Intra-Cellular Caplyta patent extension granted, says RBC Capital 08/04/23 Cantor Fitzgerald Intra-Cellular price target raised to $98 from $90 at Cantor Fitzgerald 07/06/23 Needham ... Create up to 12 portfolios with 150 stocks each, and see how active they are in market news. ...Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. February, 24 2021 07:30 AM ... Feb. 24, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...
Nov 23, 2023 · Shares of Intra-Cellular Therapies (ITCI Quick Quote ITCI - Free Report) have gained 22.4% over the past four weeks to close the last trading session at $59.26, but there could still be a solid ... Intra-Cellular Therapies Inc. research and ratings by Barron's. View ITCI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 expecting ITCI to ...In terms of how INTRA-CELLULAR THERAPIES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 3826.61% of that group. ITCI has a greater number of analysts covering the stock than 3418.44% of stocks in the mid market cap category.
Intra-Cellular Therapies Market Cap: 5.69B, Enterprise value: 5.39B, P/E: -21.66, PEG ratio: -0.97, EPS: -1.54, Revenue: 418.10M, EBITDA: -172.56M, ...April 27, 2023 at 10:03 AM · 5 min read. Wall Street expects a year-over-year increase in earnings on higher revenues when Intra-Cellular Therapies (ITCI) reports results for the quarter ended ...Over the past five years, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has witnessed a stock price increase of 162.29%. ... Don’t go anywhere, rather, stay in the stock market, ...Find the latest on option chains for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com ... Financial analysts and individual investors can rely on the chain to gauge the stock's ...View the basic ITCI option chain and compare options of Intra-Cellular Therapies, Inc. on Yahoo Finance.
May 4, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Nov 22, 2023 · The latest Intra-Cellular Therapies stock prices, stock quotes, news, and ITCI history to help you invest and trade smarter.
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual …Intra-Cellular Therapies Inc. research and ratings by Barron's. View ITCI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% …View Valuation. Research Intra-Cellular Therapies' (Nasdaq:ITCI) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, …If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. February, 24 2021 07:30 AM ... Feb. 24, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...
Get Intra-Cellular Therapies Inc (ITCI.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsNov 7, 2023 · The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ... Wasatch Global Investors highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc ...ITCI Intra-Cellular. 10/02/23 RBC Capital Intra-Cellular Caplyta patent extension granted, says RBC Capital 08/04/23 Cantor Fitzgerald Intra-Cellular price target raised to $98 from $90 at Cantor Fitzgerald 07/06/23 Needham ... Create up to 12 portfolios with 150 stocks each, and see how active they are in market news. ...Find the latest dividend history for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com.
ITCI has received 7 recent reviews, and they all concur – this is a stock to buy, making the Strong Buy consensus view unanimous. The shares are priced at $50.8 and the $62.71 average price ...
The Zacks Consensus Estimate for ITCI's full-year earnings has moved 14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.Find the latest Financials data for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios. Stocks with a Value Score from 81-100 are considered deep value, those with a score between 61-80 are value and so on. Intra-Cellular Therapies Inc has a Value Score of 5, which is Ultra Expensive.TipRanks | Stock Market Research, News and Analyst Forecasts ... The Zacks Consensus Estimate for ITCI's full-year earnings has moved 14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.JuSun/iStock via Getty Images. Intra-Cellular Therapies ( ITCI +10.0%) has bounced back from a one-month low as several Wall Street analysts pointed to the strong performance of the company’s ...A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 expecting ITCI to ...
March 31, 2023 at 11:30 AM · 4 min read. It has been about a month since the last earnings report for Intra-Cellular Therapies (ITCI). Shares have added about 20.5% in that time frame ...
Nov 7, 2023 · The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...
Intra-Cellular Therapies (ITCI) Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies on October 6 and set a price target of $95.00 . The company’s shares closed last ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...Wall Street expects a year-over-year increase in earnings on higher revenues when Intra-Cellular Therapies (ITCI) reports results for the quarter...On November 2, 2023, Intra-Cellular Therapies Inc (ITCI) stock had a median target price of $76.00, according to 13 analysts offering 12-month price forecasts. The high estimate for the stock was $100.00, while the low estimate was $59.00. The consensus among 14 investment analysts was to buy stock in Intra-Cellular Therapies Inc.Nov 2, 2023 · The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average for the last 20 days is -0.20% for ITCI stock ... Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit. However, analysts -- and likely investors -- had been bracing for worse ...Shares of NASDAQ:ITCI opened at $62.84 on Monday. The business’s fifty day moving average price is $54.03 and its two-hundred day moving average price is $58.02. The stock has a market ...Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc. On September 19, 2023, Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold ...
May 4, 2023 · Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ... 0001193125-20-214163.txt : 20200810 0001193125-20-214163.hdr.sgml : 20200810 20200810081722 ACCESSION NUMBER: 0001193125-20-214163 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTIntra-Cellular Therapies Inc’s trailing 12-month revenue is $365.8 million with a -50.4% profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $-2.089 per share for the current fiscal year. Intra-Cellular Therapies Inc does not currently pay a dividend.In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the offering, shares of Intra-Cellular common stock will commence trading on the NASDAQ Global Select Market tomorrow morning under the ticker "ITCI."Instagram:https://instagram. mutf aepgxfinancial advisors in new jerseyart investment portfoliobest day trading programs Nov 7, 2023 · Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ... otc stock platformsnvidia stock buy The company increased its Caplyta net product sales in the range of $445-$465 million (previously $430-$455 million) for the full-year 2023. Intra-Cellular, however, maintained its full-year 2023 ...Dec 1, 2023 · According to 8 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $78.5, which is an increase of 24.92% from the latest price. Price Target taiwan etf The firm decreased its portfolio allocation in ITCI by 99.89% over the last quarter. ITOT - iShares Core S&P Total U.S. Stock Market ETF holds 89K shares representing 0.09% ownership of the company.Intra-Cellular Therapies Inc (ITCI) USD0.0001 ... Market cap. ... Data delayed by at least 15 minutes. * To buy US shares you must first complete and return a US ...Biotech Alert: Searches spiking for these stocks today May 5, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and ...